Description
Telmisartan (Micardis) is an angiotensin II receptor type 1 (AT1) antagonist from the sartan class, clinically approved for hypertension treatment. What distinguishes Telmisartan from other sartans: additional partial PPAR-gamma agonist action mediating metabolic effects.
Per study reports Telmisartan blocks the AT1 receptor and thereby lowers blood pressure via vasodilation and aldosterone inhibition. The additional PPAR-gamma activation acts insulin sensitivity-promoting and improves the lipid profile - a valuable effect in the recreational community where anabolic-induced blood pressure and lipid changes matter.
Pharmacokinetically orally bioavailable with about 24-hour half-life - the longest of the sartan class. A once-daily dose suffices for stable 24-hour blood pressure effect.
In recreational research practice Telmisartan is often used as accompanying compound in anabolic cycles to control anabolic-related blood pressure rise. The additional PPAR-gamma effects are a bonus.
Known effects in studies: orthostatic hypotension (especially at start), hyperkalemia (rare), occasional dizziness. Tends to be very well tolerated compared to other antihypertensives.
You can order Telmisartan as oral tablets in one bottle with 40mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Telmisartan is an approved AT1 receptor blocker and is considered very well tolerated compared to other antihypertensives, but it has a clearly documented effect profile that primarily concerns circulation.
Documented in clinical studies:
- Orthostatic hypotension: a drop in blood pressure on changing position, especially at the start of use, is the most commonly documented effect and follows directly from the blood-pressure-lowering mechanism.
- Dizziness: occasional dizziness is described in the literature and is usually related to the blood pressure effect.
- Potassium increase: hyperkalemia is rarely documented but belongs to the known profile of the sartan class.
- Long half-life: with a roughly 24-hour half-life the duration of action is long. The blood pressure effect builds up stably over several days, which is relevant in the first 1-2 weeks.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR-gamma-Modulating Activity - Hypertension 2004, Benson et al: first identification of telmisartan as a partial PPAR-gamma agonist.
- Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome - Cardiovascular Diabetology 2005, Vitale et al: comparison study of telmisartan vs losartan with insulin sensitivity and lipid effects.
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events - NEJM 2008, ONTARGET Investigators: ONTARGET trial with cardiovascular endpoint equivalence of telmisartan vs ramipril.
- Structural basis for telmisartan-mediated partial activation of PPAR gamma - Hypertension Research 2012, Amano et al: structural analysis of partial PPAR-gamma activation by telmisartan.
- Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes - Journal of Clinical Pharmacy and Therapeutics 2011, Suksomboon et al: systematic review of telmisartan’s insulin sensitivity effect.
